APLIF Stock Appili Therapeutics (APLIF, $0.03) entered Uptrend as Momentum indicator ascends above 0 level on Dec 12, 2024
at Tickeron.com
Momentum Indicator for APLIF turns positive, indicating new upward trend
APLIF saw its Momentum Indicator move above the 0 level on December 12, 2024. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 116 similar instances where the indicator turned positive. In of the 116 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for APLIF just turned positive on December 06, 2024. Looking at past instances where APLIF's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
APLIF moved above its 50-day moving average on December 06, 2024 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for APLIF crossed bullishly above the 50-day moving average on December 03, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 26 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where APLIF advanced for three days, in of 143 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
APLIF broke above its upper Bollinger Band on November 26, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for APLIF entered a downward trend on December 03, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). APLIF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (9.025) is also within normal values, averaging (260.687).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. APLIF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APLIF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
General Information
Industry Biotechnology